Skip to main content
. 2022 Jul 26;43(45):4722–4735. doi: 10.1093/eurheartj/ehac363

Figure 1.

Figure 1

Cardiac systemic light-chain amyloid regression on serial cardiovascular magnetic resonance scans at baseline (top row) and after treatment with chemotherapy at 6 months (second row) and 1 year (third row). Reductions in native T1, late gadolinium enhancement, and extracellular volume within the myocardium are demonstrated progressively over the course of treatment.